You are here
Extend Biosciences Inc.
UEI: DZTKWESJQQ99
# of Employees: 2
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: Yes
Award Charts
Award Listing
-
Long Duration, Novel Opioid Medical Countermeasure for Intramuscular Injection
Amount: $161,589.36Threats using chemical and biological weapons are ever-evolving and expanding in scope, underscoring the need for preparedness; therefore, the development and procurement of medical countermeasures is ...
SBIRPhase I2020Department of Defense Office for Chemical and Biological Defense -
Long-acting PTH for hypoparathyroidism
Amount: $3,000,000.00Project Summary Hypoparathyroidism is a rare disease that results from a deficiency or inability to make sufficient amounts of parathyroid hormone (PTH). Untreated or inadequately treated hypoparathyr ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Long-acting ghrelin for neuropathy
Amount: $535,325.00Project Summary Neuropathy is an acquired disease that can lead to debilitating chronic pain affectingtoof the general populationAmong patients with symptomatic neuropathysleep disturbancesanxiety and ...
SBIRPhase I2019Department of Health and Human Services National Institutes of Health -
Long-acting ghrelin for the treatment of ARS
Amount: $600,000.00Project Summary The threat of a radiation attack or accident isunfortunatelyall too real and could potentially affect a large enough population so as to overwhelm the medical systemTo be prepared for ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
Long-acting ghrelin for the treatment of cancer cachexia
Amount: $2,212,084.00Project Summary Cachexia is a complex syndrome characterized by involuntary weight loss and skeletal muscle wasting that leads to fatigueweakness and a loss of appetite that is not reversed by increas ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Long-acting PTH for hypoparathyroidism
Amount: $3,730,799.00Project Summary Hypoparathyroidism is a rare disease that results from a deficiency or inability to make sufficient amounts of parathyroid hormonePTHUntreated or inadequately treated hypoparathyroidis ...
SBIRPhase II2017Department of Health and Human Services National Institutes of Health -
Ultralong acting insulin for diabetes
Amount: $350,000.00Project Summary Insulin replacement therapy has saved numerous lives of Type diabetic patients since it was established in the andapos s Currently multiple fast intermediate and longer acti ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
SBIR Phase II: A platform technology that significantly improves drug delivery
Amount: $741,634.00The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is the development of a drug delivery platform that can improve a drug?s properties such that ...
SBIRPhase II2015National Science Foundation -
Long acting PTH for hypoparathyroidism
Amount: $306,738.00DESCRIPTION provided by applicant Hypoparathyroidism is a rare disease that results from a deficiency or inability to make sufficient amounts of parathyroid hormone PTH Untreated or inadequately ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
Enhancing the Pharmacokinetic Profile of Protein-based Drugs
Amount: $999,998.00Many protein-based drugs have limited efficacy due to a short half-life or require intravenous delivery because of low bioavailability. Extend Biosciences is developing proprietary carrier molecules t ...
SBIRPhase II2014Department of Defense Office for Chemical and Biological Defense
